Libivirumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458269945

| type = mab

| mab_type = mab

| source = u

| target = Hepatitis B surface antigen

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 569658-79-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = J1R33H8X7A

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6598 | H=10232 | N=1788 | O=2060 | S=46

}}

Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.[https://web.archive.org/web/20051104055541/http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf WHO Drug Information]{{cite journal| vauthors = Shouval D, Terrault N, Galun E, Samuel D, Gane E, Pruett T, Rustgi V, Shrestha R, Mukherjee S, Stravitz R, Reddy R | display-authors = 6 |year=2006|title=Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatitis B Virus (Hbv) in Liver Transplant (Lt) Recipients|journal=Hepatology|volume=44|issue=4|doi=10.1002/hep.21395 |pages=188A–700A [196A] |doi-access=free}}